Only about 3 percent of oncology patients participate in clinical trials, and there are substantial demographic disparities between trial participants and the general population, making it difficult to extrapolate study results to make evidence-based treatment recommendations and predict real-world benefits.  According to Clifford Hudis, M.D., CEO of ASCO, this calls for a need to explore health technology solutions that tap into real-world data, such as big data sets and evidence from prospective research studies, to predict successful cancer treatment. (OncLive)